SCHEMBL2861319

SCHEMBL2861319

CC(C)(C#N)c1cccc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C=Cc5ccccc5)sc4n3)c(Cl)cc2F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 15/20 0.41
KDR P35968 11/20 0.41
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
HSP90AA1 P07900 1/20 0.39
KMT2A Q03164 1/20 0.39
RAF1 P04049 2/20 0.39
IKBKB O14920 1/20 0.37
ERBB2 P04626 1/20 0.37
CDK1 P06493 1/20 0.37
PDGFRB P09619 1/20 0.37
KIT P10721 1/20 0.37
SRC P12931 1/20 0.37
PDGFRA P16234 1/20 0.37
FGFR3 P22607 1/20 0.37
MAP2K1 Q02750 1/20 0.37
TEK Q02763 1/20 0.37
MAPK14 Q16539 1/20 0.37
AURKB Q96GD4 1/20 0.37
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861318 1.00 BRAF (0.41) BRAFKDRMAPTMEN1HSP90AA1
SCHEMBL2853177 0.90 BRAF (0.40) BRAFKDRMAPTMEN1KMT2A
SCHEMBL2853171 0.90 BRAF (0.40) BRAFKDRMAPTMEN1KMT2A
SCHEMBL2851399 0.87 BRAF (0.44) BRAFKDRRAF1IKBKBERBB2
SCHEMBL2861028 0.87 BRAF (0.45) BRAFKDRRAF1IKBKBERBB2
SCHEMBL2858695 0.87 BRAF (0.45) BRAFKDRRAF1IKBKBERBB2
SCHEMBL2853332 0.86 BRAF (0.55) BRAFKDRRAF1IKBKBERBB2
SCHEMBL2855383 0.86 BRAF (0.43) BRAFKDRRAF1IKBKBERBB2
SCHEMBL2853214 0.84 BRAF (0.41) BRAFKDRRAF1
SCHEMBL2862007 0.82 BRAF (0.47) BRAFKDRRAF1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 BRAF 1/4885KDR 983/4885MAPT 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.